Evolution of the Average Target: Jade Biosciences, Inc.

Evolution of the Target Price: Jade Biosciences, Inc.

Changes in Analyst Recommendations: Jade Biosciences, Inc.

5c8.ouJ1WtkKSQ1oMDxxavuVvq4yRpBnonIxQafQuA7Jf2Q.7JInFYBOO1sGeG88GLbw1tpjFaIj0hNUddbm8G2gTgzHtEU9rV0RQlxRSw~9a13714caced3035fe28d770fef813fe
06-15 UBS Initiates Jade Biosciences at Buy With $45 Price Target MT
06-01 Wedbush Raises Price Target on Jade Biosciences to $45 From $34, Maintains Outperform Rating MT
05-08 Wedbush Raises Price Target on Jade Biosciences to $34 From $24, Keeps Outperform Rating MT
05-08 Wedbush Raises Price Target on Jade Biosciences to $34 From $24, Maintains Outperform Rating MT
03-09 William Blair Initiates Coverage on Jade Biosciences With Outperform Rating MT
01-07 HC Wainwright Initiates Jade Biosciences at Buy With $25 Price Target MT
12-23 Wedbush Adjusts Price Target on Jade Biosciences to $24 From $19, Maintains Outperform Rating MT
11-14 Wedbush Adjusts Price Target on Jade Biosciences to $19 From $18, Maintains Outperform Rating MT
25-10-09 BTIG Initiates Jade Biosciences at Buy With $28 Price Target MT
25-08-14 Wedbush Adjusts Price Target on Jade Biosciences to $18 From $17, Maintains Outperform Rating MT
25-06-16 Guggenheim Upgrades Jade Biosciences to Buy From Neutral, Price Target is $14 MT
25-05-05 Stifel Nicolaus Initiates Coverage on Jade Biosciences With Buy Rating, $19 Price Target MT
25-05-02 TD Cowen Initiates Coverage on Jade Biosciences With Buy Rating MT
24-06-18 Guggenheim Downgrades Aerovate Therapeutics to Neutral From Buy MT
24-06-18 TD Cowen Downgrades Aerovate Therapeutics to Hold From Buy MT
24-06-18 Evercore ISI Downgrades Aerovate Therapeutics to In Line From Outperform, Adjusts Price Target to $2 From $27 MT
24-06-17 Top Midday Decliners MT
24-06-17 Jefferies Downgrades Aerovate Therapeutics to Hold From Buy, Cuts Price Target to $2 From $65; Shares Plummet MT
24-06-17 Wells Fargo Downgrades Aerovate Therapeutics to Equalweight From Overweight, Cuts Price Target to $2 From $35; Shares Plummet MT
24-06-17 BTIG Downgrades Aerovate Therapeutics to Neutral From Buy MT
24-06-17 Wedbush Downgrades Aerovate Therapeutics to Neutral From Outperform, Adjusts Price Target to $3 From $41 MT
23-08-15 Wedbush Adjusts Aerovate Therapeutics Price Target to $48 From $50, Maintains Outperform Rating MT
23-05-17 Wedbush Lowers Aerovate Therapeutics' Price Target to $50 From $54, Keeps Outperform Rating MT
23-03-01 Guggenheim Initiates Aerovate Therapeutics at Buy With $36 Price Target MT
22-12-12 Wedbush Raises Aerovate Therapeutics' PT to $54 From $27 on Increased Confidence in Inhaled TKIs, AV-10; Keeps Outperform Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+120.76%
+28.75%
+10.49%
+49.33%
+31.64%
+58.27%
+24.19%
-6.33%
+8.87%
+38.06%
Average +36.40%
Weighted average by Cap. +29.54%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
21.97USD
Average target price
48.50USD
Spread / Average Target
+120.76%
High Price Target
74.00USD
Spread / Highest target
+236.82%
Low Price Target
40.00USD
Spread / Lowest Target
+82.07%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

UBS
Wedbush
Edgewater Research
William Blair & Co.
HC Wainwright
BTIG
Guggenheim
Stifel Nicolaus
TD Cowen
Evercore ISI
Jefferies & Co.
Wells Fargo Securities
Cowen
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
21.97USD
Average target price
48.50USD
Spread / Average Target
+120.76%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. JBIO Stock
  4. Consensus Jade Biosciences, Inc.
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!